Johnson & Johnson expects to receive FDA approval next year for a wrinkle-reducing injection similar to Allergan's Botox. Allergan already faces competition from Valeant's Dysport and Merz's Xeomin, but it has an 85% market share.
J&J threatens to put a wrinkle in Botox's dominance
SmartBrief Job Listings for Health Care
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|
|Director Account Management||
Samaritan Health Services
|Hospital Medical Device Sales||
Linda Hertz Group